Status:
RECRUITING
Therapy to Maintain Remission in Dilated Cardiomyopathy
Lead Sponsor:
Imperial College London
Collaborating Sponsors:
Royal Brompton & Harefield NHS Foundation Trust
Conditions:
Heart Failure
Cardiomyopathy, Dilated
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
One third of patients diagnosed with heart failure demonstrate left ventricular reverse remodelling and recovery of cardiac function following a period of medical therapy. The TRED-HF trial investigat...
Detailed Description
One third of patients diagnosed with heart failure demonstrate left ventricular reverse remodelling and recovery of cardiac function following a period of medical therapy. These patients have an excel...
Eligibility Criteria
Inclusion
- a diagnosis of dilated cardiomyopathy,
- previous left ventricular ejection fraction (LVEF) \<40% (on echocardiography or cardiovascular magnetic resonance \[CMR\]),
- current LVEF \>50% with normal left ventricular end-diastolic volume (LVEDV),
- plasma NT-pro-BNP\<250ng/L,
- New York Heart Association (NYHA) class I,
- sinus rhythm,
- taking a beta-blocker and an angiotensin converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB) or sacubitril-valsartan, along with either a mineralocorticoid receptor antagonist (MRA) and/or sodium glucose co-transporter 2 inhibitor (SGLT2i).
Exclusion
- Atrial fibrillation,
- prior sustained ventricular tachycardia or fibrillation,
- a known likely pathogenic or pathogenic variant in LMNA/DSP/FLNC/RBM20,
- sudden cardiac or heart failure death in a first degree relative \<50 years,
- contraindication to CMR,
- estimated glomerular filtration rate (eGFR) \<60mls/min,
- planned pregnancy,8) active myocardial inflammation,
- 9\) diabetes mellitus managed with an SGLT2i, 10) urinary albumin-to-creatine ratio of 200-5000 (mg:g) and eGFR\< 75mls/min.
Key Trial Info
Start Date :
December 2 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 15 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06091475
Start Date
December 2 2023
End Date
September 15 2026
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Brompton Hospital
London, United Kingdom